Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02UQG
|
|||
| Former ID |
DIB001194
|
|||
| Drug Name |
RDEA-436
|
|||
| Synonyms |
MEK inhibitor, Ardea; MEK inhibitor (cancer), Bayer; MEK inhibitor 200 series (cancer), Bayer HealthCare; MEK inhibitor 200 series (inflammation), Ardea; Mitogen-activated ERK kinase inhibitor (inflammation), Ardea; RDEA-436 (cancer), Bayer HealthCare; RDEA-436 (cancer/inflammation), Ardea
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Discontinued in Phase 1 | [1] | |
| Company |
Ardea Biosciences Inc
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028258) | |||
| REF 2 | Clinical pipeline report, company report or official report of MedKoo Biosciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.